Özlem Demirpençe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Özlem Demirpençe has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Halef Okan Doğan
Sivas Cumhuriyet Üniversitesi
2 shared publications - Ahmet Omma
Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, University of Health Sciences, 06800 Ankara, Turkey
1 shared publication - Hasan Şahin
Ankara Şehir Hastanesi
1 shared publication - Hayrettin Yavuz
University of Virginia School of Medicine
1 shared publication - Hüseyin Aydın
Department of Medical Biochemistry, Faculty of Medicine, Sivas Cumhuriyet University, Türkiye
1 shared publication - Mehmet Bakır
Medicana Hospital
1 shared publication
Latest Publications
- Open Access
- 1 January 2016
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (12) , 1902-1906
Decreased Chitotriosidase Activity and Levels in Familial Mediterranean Fever
Doğan HO, et al. J Korean Med Sci. 2016 Dec;31(12):1902-1906. https://doi.org/10.3346/jkms.2016.31.12.1902
- 1 January 2016
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (12) , 1902-1906
Open AccessDecreased Chitotriosidase Activity and Levels in Familial Mediterranean Fever
Doğan HO, et al. J Korean Med Sci. 2016 Dec;31(12):1902-1906. https://doi.org/10.3346/jkms.2016.31.12.1902
- Open Access
- 1 January 2016
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 69 (6) , 505-509
Presepsin Levels of Patients with Crimean-Congo Hemorrhagic Fever
Levels of presepsin (a soluble cluster of differentiation subtype 14 [CD14]) are thought to increase in cases of bacterial infection. CD14 has also been found to play a role in the pathogenesis of various viral diseases. Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic arboviral infection. Our study focuses on presepsin levels as a biomarker for CCHF. Serum presepsin levels in a CCHF group (n = 59) and control group (n = 28) were compared. Patients with CCHF were classified according to severity grading score as having mild, moderate, or severe infection and were allocated to corresponding subgroups (groups 1, 2, and 3, respectively). Presepsin levels were measured in serum samples by using a commercial enzyme-linked immunosorbent assay kit. The mean presepsin levels in the CCHF group as a whole and the healthy group were found to be significantly different (1,499.46 ± 411.96 pg/ml and 430.68 ± 61.21 pg/ml, respectively). The mean presepsin levels of the CCHF subgroups (1, 2 and 3) and the healthy group were also found to be significantly different (1,204.53 ± 371.18, 1,464.21 ± 338.37, 2,007.36 ± 82.18, and 430.68 ± 61.21 pg/ml, respectively) (p < 0.05). We also found that as the severity of the disease increased, the presepsin level also increased. We postulate that the presepsin levels could be used as a supportive biomarker for diagnosis and follow-up of the disease.
- 1 January 2016
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 69 (6) , 505-509
Open AccessPresepsin Levels of Patients with Crimean-Congo Hemorrhagic Fever
Levels of presepsin (a soluble cluster of differentiation subtype 14 [CD14]) are thought to increase in cases of bacterial infection. CD14 has also been found to play a role in the pathogenesis of various viral diseases. Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic arboviral infection. Our study focuses on presepsin levels as a biomarker for CCHF. Serum presepsin levels in a CCHF group (n = 59) and control group (n = 28) were compared. Patients with CCHF were classified according to severity grading score as having mild, moderate, or severe infection and were allocated to corresponding subgroups (groups 1, 2, and 3, respectively). Presepsin levels were measured in serum samples by using a commercial enzyme-linked immunosorbent assay kit. The mean presepsin levels in the CCHF group as a whole and the healthy group were found to be significantly different (1,499.46 ± 411.96 pg/ml and 430.68 ± 61.21 pg/ml, respectively). The mean presepsin levels of the CCHF subgroups (1, 2 and 3) and the healthy group were also found to be significantly different (1,204.53 ± 371.18, 1,464.21 ± 338.37, 2,007.36 ± 82.18, and 430.68 ± 61.21 pg/ml, respectively) (p < 0.05). We also found that as the severity of the disease increased, the presepsin level also increased. We postulate that the presepsin levels could be used as a supportive biomarker for diagnosis and follow-up of the disease.